Pfizer logo

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for a Potential Biosimilar to Humira (adalimumab), PF-06410293

January 5, 2017 Pfizer Inc. has announced that the confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12. This trial is evaluating the safety, efficacy, and immunogenicity of PF-06410293 compared to Humira (adalimumab), each taken in combination with methotrexate, in … Continue reading Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for a Potential Biosimilar to Humira (adalimumab), PF-06410293

Advertisements
Best Pharma Companies at a Glance: Pfizer - Igeahub

Best Pharma Companies at a Glance: Pfizer

Pfizer is a research-based pharmaceutical company engaged in the wellness, prevention and treatment for diseases across a broad range of therapeutic areas. The company operates through Innovative Health and Established Health businesses. Innovative Health encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial … Continue reading Best Pharma Companies at a Glance: Pfizer

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016

Pfizer logo

European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

November 10, 2016 Pfizer Inc. has announced that the European Commission (EC) has approved IBRANCE® (palbociclib) for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The approval is for IBRANCE for using in combination with an aromatase inhibitor. It also covers the use of IBRANCE combining … Continue reading European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

Pfizer logo

Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

November 15, 2016 Pfizer Inc. has announced that new results from the Phase 3 Oral Psoriatic Arthritis TriaL(OPAL) studies, Broaden and Beyond, will be presented at the ACR/ARHP Annual Meeting 2016, which will be held in November 11-16, in Washington, DC. OPAL Broaden and OPAL Beyond evaluated the safety and efficacy of XELJANZ® (tofacitinib citrate) in adult patients with … Continue reading Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

pfizer-nci

Pfizer Collaborates with National Cancer Institute to Study Three Immunotherapy Agents that Target Multiple Cancers

November 14, 2016 Pfizer Inc. has announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), which is a part of the National Institutes of Health (NIH). According to this agreement, Pfizer will collaborate with NCI’s Center for Cancer Research (CCR) for arranging and conducting preclinical and clinical … Continue reading Pfizer Collaborates with National Cancer Institute to Study Three Immunotherapy Agents that Target Multiple Cancers

Pfizer logo

Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatoid Arthritis and Psoriatic Arthritis

November 7, 2016 Pfizer Inc. has announced that it will present 20 abstracts for XELJANZ® (tofacitinib citrate) at the upcoming 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). More importantly, for the first time, results from the two pivotal Phase 3 OPAL (Oral Psoriatic Arthritis TriaL) studies of tofacitinib – the only Janus kinase (JAK) inhibitor under investigation … Continue reading Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatoid Arthritis and Psoriatic Arthritis

Pfizer Merck Igea Luca dezzani

EMA Validates the Marketing Authorization Application for Avelumab for Treating Metastatic Merkel Cell Carcinoma

  October 31, 2016 KGaA, Darmstadt, Germany, and Pfizer Inc. have announced that the European Medicines Agency (EMA) has validated Marketing Authorization Application (MAA) for avelumab for the proposed indication of metastatic Merkel cell carcinoma (MCC). It is an aggressive and rare skin cancer, which impacts approximately 2,500 Europeans a year. If approved, avelumab, an investigational … Continue reading EMA Validates the Marketing Authorization Application for Avelumab for Treating Metastatic Merkel Cell Carcinoma

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – September and October, 2016

  Bristol-Myers Squibb’s ORENCIA® (abatacept) is Approved by European Commission for the Treatment of Adult Patients with Rheumatoid Arthritis September 6, 2016 Bristol-Myers Squibb Company has announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, combined with methotrexate (MTX), for treating highly active and progressive disease in adult patients with rheumatoid … Continue reading Top Pharma News – September and October, 2016